Targeted Delivery of CRISPR/Cas9-Mediated Cancer Gene Therapy via Liposome-Templated Hydrogel Nanoparticles

Advanced Functional Materials
Zeming ChenJiangbing Zhou

Abstract

Due to its simplicity, versatility, and high efficiency, the clustered regularly interspaced short palindromic repeat (CRISPR)/Cas9 technology has emerged as one of the most promising approaches for treatment of a variety of genetic diseases, including human cancers. However, further translation of CRISPR/Cas9 for cancer gene therapy requires development of safe approaches for efficient, highly specific delivery of both Cas9 and single guide RNA to tumors. Here, novel core-shell nanostructure, liposome-templated hydrogel nanoparticles (LHNPs) that are optimized for efficient codelivery of Cas9 protein and nucleic acids is reported. It is demonstrated that, when coupled with the minicircle DNA technology, LHNPs deliver CRISPR/Cas9 with efficiency greater than commercial agent Lipofectamine 2000 in cell culture and can be engineered for targeted inhibition of genes in tumors, including tumors the brain. When CRISPR/Cas9 targeting a model therapeutic gene, polo-like kinase 1 (PLK1), is delivered, LHNPs effectively inhibit tumor growth and improve tumor-bearing mouse survival. The results suggest LHNPs as versatile CRISPR/Cas9-delivery tool that can be adapted for experimentally studying the biology of cancer as well as for clinica...Continue Reading

References

Mar 17, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·John F Deeken, Wolfgang Löscher
Oct 16, 2007·Journal of Controlled Release : Official Journal of the Controlled Release Society·Shyh-Dar Li, Leaf Huang
Dec 8, 2009·Cancer Cell·Kazuki N SugaharaErkki Ruoslahti
Nov 26, 2010·Nature Biotechnology·Mark A KayZhi-Ying Chen
Sep 16, 2011·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Aaron J CarmanMargaret S Bynoe
Dec 6, 2011·Nature Materials·Jiangbing ZhouW Mark Saltzman
Feb 1, 2012·The Cancer Journal·Jiangbing ZhouW Mark Saltzman
Jun 30, 2012·Science·Martin JinekEmmanuelle Charpentier
Oct 9, 2012·Journal of Controlled Release : Official Journal of the Controlled Release Society·Fabrizio SalomoneFabio Beltram
Jan 5, 2013·Science·Le CongFeng Zhang
Jul 3, 2013·Proceedings of the National Academy of Sciences of the United States of America·Jiangbing ZhouW Mark Saltzman
Apr 29, 2014·Nature Biotechnology·Shengdar Q TsaiJ Keith Joung
Jul 31, 2014·Nature Methods·Neville E SanjanaFeng Zhang
Sep 5, 2014·Biotechnology Journal·Elena SenísDirk Grimm
Oct 20, 2014·Nature Biotechnology·Lukasz SwiechFeng Zhang
May 25, 2015·Journal of Biotechnology·Xiquan LiangJonathan D Chesnut
Mar 2, 2016·Proceedings of the National Academy of Sciences of the United States of America·Ming WangQiaobing Xu
May 6, 2016·Annual Review of Chemical and Biomolecular Engineering·Christopher E Nelson, Charles A Gersbach
May 21, 2016·Molecular Therapy : the Journal of the American Society of Gene Therapy·Kamila S GwiazdaAndrew M Scharenberg

❮ Previous
Next ❯

Citations

Jul 19, 2019·Angewandte Chemie·Lingmin ZhangXingyu Jiang
Nov 2, 2019·Nanoscale·Piyush K JainSangeeta N Bhatia
May 5, 2020·Journal of Materials Chemistry. B, Materials for Biology and Medicine·Yan GongShubiao Zhang
May 1, 2018·Macromolecular Rapid Communications·Zhen ZhangJunjiu Huang
Nov 6, 2018·Chembiochem : a European Journal of Chemical Biology·Le WangXingyu Jiang
Dec 24, 2018·Journal of Biological Engineering·Alessio BiagioniMario Del Rosso
Dec 5, 2019·Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology·Fengqian ChenQi Liu
Feb 9, 2019·Biomaterials Science·Joon Eoh, Luo Gu
Jun 26, 2018·Advanced Science·Yinnan Chen, Yanmin Zhang
May 28, 2019·Gels·Andreas BlaeserDaniela F Duarte Campos
Jul 1, 2020·Advanced Science·Xiaofeng DaiKostya Ken Ostrikov
Oct 21, 2020·Nature Reviews. Drug Discovery·Elizabeth M PortoGene W Yeo
Oct 28, 2020·Biomaterials Science·Yanan LiYouqing Shen
Oct 9, 2020·International Journal of Molecular Sciences·Karim ShalabyOmar El-Agnaf
Jul 1, 2020·Advanced Drug Delivery Reviews·Nina FilipczakVladimir P Torchilin
Nov 24, 2019·Advanced Drug Delivery Reviews·Cong-Fei XuJun Wang
Dec 12, 2020·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Adam Chyzy, Marta E Plonska-Brzezinska
Nov 22, 2020·Journal of Materials Chemistry. B, Materials for Biology and Medicine·Yu TaoMingqiang Li
Nov 12, 2020·Journal of Controlled Release : Official Journal of the Controlled Release Society·Shuyi Xiao, Liang Chen
Apr 1, 2021·Journal of Controlled Release : Official Journal of the Controlled Release Society·Jing-Jun NieFu-Jian Xu
May 12, 2021·Cellular and Molecular Life Sciences : CMLS·Biyao YangWei Deng
Nov 1, 2019·Nature Reviews. Materials·Sheng TongGang Bao
Aug 3, 2021·Journal of Drug Delivery Science and Technology·Bhaargavi AshokMarissa E Wechsler
Jul 16, 2021·Biological Procedures Online·Ziyi ZhaoYi Sang
Jul 22, 2021·Journal of Biomaterials Science. Polymer Edition·Lijun ZhaoWeiyi Chen
Jul 30, 2021·Drug Delivery and Translational Research·Behzad BaradaranSomayeh Hallaj-Nezhadi

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR (general)

Clustered regularly interspaced short palindromic repeats (CRISPR) are DNA sequences in the genome that are recognized and cleaved by CRISPR-associated proteins (Cas). CRISPR-Cas system enables the editing of genes to create or correct mutations. Discover the latest research on CRISPR here.

CRISPR for Genome Editing

Genome editing technologies enable the editing of genes to create or correct mutations. Clustered regularly interspaced short palindromic repeats (CRISPR) are DNA sequences in the genome that are recognized and cleaved by CRISPR-associated proteins (Cas). Here is the latest research on the use of CRISPR-Cas system in gene editing.

CRISPR Ribonucleases Deactivation

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on mechanisms that underlie deactivation of CRISPR ribonucleases. Here is the latest research.

CRISPR Genome Editing & Therapy

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of this system for gene editing and therapy in human diseases.

CRISPR in Cancer

CRISPR-Cas system enables the editing of genes to create or correct mutations. Given that genome instability and mutation is one of the hallmarks of cancer, the CRISPR-Cas system is being explored to genetically alter and eliminate cancer cells. Here is the latest research.